Upstream Bio to Participate in the Piper Sandler 36th Annual Healthcare Conference
Upstream Bio to Participate in the Piper Sandler 36th Annual Healthcare Conference
Upstream Bio is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. The Company is developing verekitug, the only known antagonist currently in clinical development that targets the receptor for thymic stromal lymphopoietin, a cytokine which is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune mediated diseases. The Company has advanced this highly potent monoclonal antibody into separate Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and plans to initiate development in chronic obstructive pulmonary disease. Upstream Bio's team is committed to maximizing verekitug's unique attributes to address the substantial unmet needs for patients underserved by today's standard of care. To learn more, please visit .WALTHAM, Mass., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced that Rand Sutherland, MD, MPH, Upstream Bio's CEO, will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on December 3, 2024 at 2:00 p.m. ET.
美國馬薩諸塞州沃爾瑟姆，2024年11月21日（環球新聞通訊社）-- Upstream Bio, Inc.（納斯達克：UPB）是一家臨床階段公司，專注於開發治療炎症疾病的療法，最初側重於嚴重呼吸疾病。今天宣佈，Upstream Bio首席執行官Rand Sutherland博士將於2024年12月3日下午2:00參與派傑投資第36屆年度醫療會議的爐邊聊天。
A live webcast of the presentation will be available under the "Events" tab on the "Investors" page on the Company's website on the day of the event. A replay of the webcast will be archived on the Company's website for 90 days following the presentation.
活動當天，公司的演示將通過網絡直播的方式在公司網站的「投資者」頁面的「事件」標籤下提供。網絡直播的回放將在演示後存檔於公司網站上90天。
About Upstream Bio
關於Upstream Bio
Upstream Bio is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. The Company is developing verekitug, the only known antagonist currently in clinical development that targets the receptor for thymic stromal lymphopoietin, a cytokine which is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune mediated diseases. The Company has advanced this highly potent monoclonal antibody into separate Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and plans to initiate development in chronic obstructive pulmonary disease. Upstream Bio's team is committed to maximizing verekitug's unique attributes to address the substantial unmet needs for patients underserved by today's standard of care. To learn more, please visit .
Upstream Bio是一家臨床階段的生物技術公司，專注於開發治療炎症疾病的療法，最初側重於嚴重呼吸疾病。該公司正在開發verekitug，這是目前在臨床開發中唯一已知的針對胸腺基質淋巴細胞刺激因子受體的拮抗劑，這是一種經過臨床驗證的炎症反應驅動因子，處於多個信號通路的上游，影響多種免疫介導的疾病。該公司已將這一高效單克隆抗體推進到治療嚴重哮喘和慢性鼻竇炎伴鼻息肉的兩個獨立的第二階段臨床試驗，並計劃在慢性阻塞性肺疾病中啓動開發。Upstream Bio的團隊致力於最大化verekitug的獨特屬性，以滿足當今治療標準無法滿足的患者的重大需求。要了解更多信息，請訪問。
CONTACT: Investor Contact:
Michael Gray
Chief Financial Officer and Chief Operating Officer
ir@upstreambio.com
Media Contact:
Teri Dahlman
Red House Communications
teri@redhousecomms.com
投資者聯繫方式:
邁克爾·格雷
首席財務官和首席運營官
ir@upstreambio.com
媒體聯繫：
特里•達爾曼
Red House Communications
teri@redhousecomms.com
譯文內容由第三人軟體翻譯。
